These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 4074917)

  • 1. [Phase II trial of treatment of metastatic renal adenocarcinoma with recombinant leukocyte interferon (rDNA IFN-alpha 2)].
    Dorval T; Palangie T; Garcia-Giralt E; Jouve M; Bretaudeau B; Falcoff F; Coninx P; Schwab D; Pouillart P
    Bull Cancer; 1985; 72(5):470-1. PubMed ID: 4074917
    [No Abstract]   [Full Text] [Related]  

  • 2. [Medical treatment of metastatic cancer of the kidney with a combination of vinblastine and recombinant interferon alpha IIa. Result of a phase I-II trial].
    Jacqmin D; Bergerat JP; Dufour P; Bollack C; Prévot G; Jurascheck F; Bailly G; Degaris S; Oberling F
    J Urol (Paris); 1987; 93(8):463-6. PubMed ID: 3440838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II trial of human recombinant beta-interferon serine in patients with renal cell carcinoma.
    Rinehart J; Malspeis L; Young D; Neidhart J
    Cancer Res; 1986 Oct; 46(10):5364-7. PubMed ID: 3756886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapy of renal cell carcinoma. 3. Interferon therapy].
    Kobayashi M; Imai K; Kiren H; Nakai K; Saruki K; Umeyama T; Ito Y; Yamanaka H; Makino T; Machida M
    Hinyokika Kiyo; 1987 Apr; 33(4):508-14. PubMed ID: 3618421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of recombinant alpha-interferon on advanced renal cell carcinoma].
    Isaka S; Okano T; Akimoto S; Shimazaki J; Murakami S; Igarashi T; Kitamura Y; Yamaguchi K; Kataumi S; Ohtsuka K
    Hinyokika Kiyo; 1985 Dec; 31(12):2209-14. PubMed ID: 3832921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European studies of interleukin-2 in metastatic renal cell carcinoma.
    Atzpodien J; Kirchner H; Hänninen EL; Körfer A; Fenner M; Menzel T; Deckert M; Franzke A; Jonas U; Poliwoda H
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):22-6. PubMed ID: 8284688
    [No Abstract]   [Full Text] [Related]  

  • 7. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
    Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of interferon-beta-serine in metastatic renal cell carcinoma.
    Kinney P; Triozzi P; Young D; Drago J; Behrens B; Wise H; Rinehart JJ
    J Clin Oncol; 1990 May; 8(5):881-5. PubMed ID: 2332772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of metastatic renal cell carcinoma with human lymphoblastoid interferon].
    Ryu S; Fukuoka M; Tamai S; Takifuji N; Sakai N; Matsui K; Negoro S; Takada M; Kusunoki Y
    Nihon Gan Chiryo Gakkai Shi; 1987 Jun; 22(5):996-1002. PubMed ID: 3694004
    [No Abstract]   [Full Text] [Related]  

  • 10. [The treatment of renal cell carcinoma with recombinant human leukocyte interferon].
    Kawamura J; Yamauchi T; Hashimura T; Yoshida O; Kohnami T; Tomoyoshi T; Ogura K; Fukuyama T; Nakagawa K
    Hinyokika Kiyo; 1985 Mar; 31(3):377-86. PubMed ID: 4025077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.
    Negrier S; Maral J; Drevon M; Vinke J; Escudier B; Philip T
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S93-8. PubMed ID: 10685667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha interferon therapy for renal cell carcinoma: summary of four collaborative trials. Cancer Research Committee.
    Aso Y; Umeda T; Niijima T
    Prog Clin Biol Res; 1989; 303():653-9. PubMed ID: 2675017
    [No Abstract]   [Full Text] [Related]  

  • 13. Combination recombinant interleukin-2, recombinant interferon-alpha, and 5-fluorouracil for treatment of metastatic renal cell carcinoma.
    Ueno NT; Zukiwski AA
    Am J Clin Oncol; 1995 Aug; 18(4):358-62. PubMed ID: 7625380
    [No Abstract]   [Full Text] [Related]  

  • 14. [Histopathologic evaluation of anti-tumor activity of alpha-interferon for renal cell carcinoma, especially in autoptic cases].
    Yamauchi T; Kawamura J; Yoshida O; Fukuyama T; Ogura K; Nakagawa K
    Hinyokika Kiyo; 1985 Sep; 31(9):1539-52. PubMed ID: 4083212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma.
    Figlin RA; Pierce WC; Belldegrun A
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):11-5. PubMed ID: 8284686
    [No Abstract]   [Full Text] [Related]  

  • 16. [Clinical efficacy of interferon-beta (MR-21) in renal cell carcinoma and cancer of the bladder].
    Niijima T
    Nihon Gan Chiryo Gakkai Shi; 1987 Jun; 22(5):928-33. PubMed ID: 3694001
    [No Abstract]   [Full Text] [Related]  

  • 17. The treatment of advanced renal cell carcinoma with a combination of human lymphoblastoid interferon-alpha and cimetidine.
    Kotake T; Kinouchi T
    Prog Clin Biol Res; 1989; 303():661-9. PubMed ID: 2780667
    [No Abstract]   [Full Text] [Related]  

  • 18. Interferon-alpha and interleukin-2 in the treatment of renal cell cancer.
    Holdener EE; Emmons RP; Brunda M; Evans L; Levitt D
    Prog Clin Biol Res; 1990; 348():61-9. PubMed ID: 2201034
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase II results with recombinant interferons: renal cell carcinoma and malignant melanoma.
    Kuzmits R; Kokoschka EM; Micksche M; Ludwig H; Flener R
    Oncology; 1985; 42 Suppl 1():26-32. PubMed ID: 4080298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open-label phase II trial of recombinant beta interferon (IFN-beta (ser)) in patients with colorectal cancer.
    Triozzi PL; Kenney P; Young D; Rinehart JJ
    Cancer Treat Rep; 1987 Oct; 71(10):983-4. PubMed ID: 3308083
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.